Sabby Management’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Sabby Management’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-228,364	Closed	-$754K	–	374
2016 Q2	$754K	Sell	228,364 -8,000	-3%	-$30.2K	0.04%	188
2016 Q1	$839K	Buy	+236,364	New	+$1.22M	0.04%	169

Other funds holding ARLZ

PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Tiger Legatus Capital Management New York $62.4M AUM 24.33% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Craig A. Drill $24.4M AUM 13.42% 1-Year Est. Return

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return

Sabby Management's ARLZ Position: Q3 2016 in Review

Sabby Management sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2016, closing a stake of 228,364 shares — an estimated $754K sold.

Sabby Management first reported a position in ARLZ in Q1 2016 and held it in 2 quarters. The position peaked at $839K in Q1 2016. 83 funds tracked by Wall St. Rank hold ARLZ as of Q3 2016.

Sabby Management reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2016 after selling out during the quarter.
Sabby Management sold 228,364 Aralez Pharmaceuticals Inc. shares in Q3 2016, an estimated $754K.
Sabby Management first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 2 quarters.
Sabby Management's Aralez Pharmaceuticals Inc. position peaked at $839K in Q1 2016.
83 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2016.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.